

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Betamethasone (0.05%) Ointment Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.



GHS Classification

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure : Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :  

Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

Betamethasone (0.05%) Ointment Formulation

Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	>= 70 - < 90
Propylene glycol monostearate	1323-39-3	>= 1 - < 5
betamethasone	378-44-9	>= 0.025 - < 0.1

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

Most important symptoms and effects, both acute and delayed : Rinse mouth thoroughly with water.
: May damage the unborn child.
: Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
: Alcohol-resistant foam
: Carbon dioxide (CO₂)
: Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Vapours may form explosive mixtures with air.
: Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
: Use water spray to cool unopened containers.
: Remove undamaged containers from fire area if it is safe to do so.
: Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
: Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
: Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
: Prevent further leakage or spillage if safe to do so.
: Retain and dispose of contaminated wash water.
: Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
: Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
: Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Mist)	5 mg/m ³	IN OEL
		STEL (Mist)	10 mg/m ³	IN OEL
		TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH
Propylene glycol monostearate	1323-39-3	TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
betamethasone	378-44-9	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

- Engineering measures** : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
4.0	23.03.2020	1688540-00007	Date of first issue: 18.05.2017

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	ointment
Colour	:	white to off-white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 93.3 °C
Evaporation rate	:	Not applicable

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Vapours may form explosive mixture with air.
Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Skin contact
Ingestion
Eye contact

Betamethasone (0.05%) Ointment Formulation

Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

Acute toxicity

Not classified based on available information.

Components:**Petrolatum:**

- Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials
- Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Propylene glycol monostearate:

- Acute oral toxicity : LD50 (Mouse): > 5,000 mg/kg

betamethasone:

- Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 4,500 mg/kg
- Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l
Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:**Petrolatum:**

- Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Propylene glycol monostearate:

- Result : No skin irritation

betamethasone:

- Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Petrolatum:**

- Species : Rabbit

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
4.0	23.03.2020	1688540-00007	Date of first issue: 18.05.2017

Method	: OECD Test Guideline 405
Result	: No eye irritation
Remarks	: Based on data from similar materials

betamethasone:

Species	: Rabbit
Result	: No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Petrolatum:**

Test Type	: Buehler Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative
Remarks	: Based on data from similar materials

betamethasone:

Exposure routes	: Dermal
Species	: Guinea pig
Result	: Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:**Petrolatum:**

Genotoxicity in vitro	: Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials

betamethasone:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

Test Type: In vitro mammalian cell gene mutation test

Betamethasone (0.05%) Ointment Formulation

Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

	Result: negative
	Test Type: Chromosome aberration test in vitro Result: positive
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Petrolatum:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Result	: negative

Reproductive toxicity

May damage the unborn child.

Components:**Petrolatum:**

Effects on fertility	: Test Type: Reproduction/Developmental toxicity screening test Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Skin contact Result: negative Remarks: Based on data from similar materials

betamethasone:

Effects on foetal development	: Species: Rabbit Application Route: Intramuscular Developmental Toxicity: LOAEL: 0.05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.
	Species: Rat Application Route: Subcutaneous Developmental Toxicity: LOAEL: 0.42 mg/kg body weight Result: Malformations were observed.

Betamethasone (0.05%) Ointment Formulation

Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

Species: Mouse
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Components:**betamethasone:**

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Petrolatum:**

Species : Rat
NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d
Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
4.0	23.03.2020	1688540-00007	Date of first issue: 18.05.2017

LOAEL	:	0.05 mg/kg
Application Route	:	Oral
Exposure time	:	28 d
Target Organs	:	Blood, thymus gland, Adrenal gland

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****betamethasone:**

Inhalation	:	Target Organs: Adrenal gland
Skin contact	:	Symptoms: Redness, pruritis, Irritation

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Petrolatum:**

Toxicity to fish	:	LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 10,000 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 10 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

betamethasone:

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamysis): > 50 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l Exposure time: 72 h

Betamethasone (0.05%) Ointment Formulation

Version 4.0 Revision Date: 23.03.2020 SDS Number: 1688540-00007 Date of last issue: 13.09.2019
Date of first issue: 18.05.2017

	Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
	NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC: 0.052 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
	NOEC: 0.07 µg/l Exposure time: 219 d Species: Oryzias latipes (Japanese medaka) Method: OECD Test Guideline 229
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 8 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	: 1,000

Persistence and degradability**Components:****Petrolatum:**

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 31 % Exposure time: 28 d Method: OECD Test Guideline 301F Remarks: Based on data from similar materials
------------------	--

Bioaccumulative potential**Components:****betamethasone:**

Partition coefficient: n-octanol/water	: log Pow: 2.11
--	-----------------

Mobility in soil

No data available

Other adverse effects

No data available

Betamethasone (0.05%) Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 13.09.2019
4.0 23.03.2020 1688540-00007 Date of first issue: 18.05.2017

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone)
Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(betamethasone)
Class : 9
Packing group : III
Labels : Miscellaneous,
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone)
Class : 9
Subsidiary risk : ENVIRONM.
Packing group : III
Labels : 9 (ENVIRONM.)
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Betamethasone (0.05%) Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
4.0	23.03.2020	1688540-00007	Date of first issue: 18.05.2017

15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
IN OEL	:	India. Permissible levels of certain chemical substances in work environment.
ACGIH / TWA	:	8-hour, time-weighted average
IN OEL / TWA	:	Time-Weighted Average Concentration (TWA) (8 hrs.)
IN OEL / STEL	:	Short-term exposure Limit STEL (15 min)

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New

SAFETY DATA SHEET



Betamethasone (0.05%) Ointment Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
4.0	23.03.2020	1688540-00007	Date of first issue: 18.05.2017

Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN